Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Previously submitted to: JMIR Public Health and Surveillance (no longer under consideration since Nov 09, 2020)

Date Submitted: Aug 28, 2020

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India

  • Dr. Animesh Ray; 
  • Dr. Komal Singh; 
  • Souvick Chattopadhyay; 
  • Farha Mehdi; 
  • Dr. Gaurav Batra; 
  • Dr. Aakansha Kumari; 
  • Dr. Ayush Agarwal; 
  • Dr. Bhavesh M; 
  • Dr. Shubham Sahni; 
  • Dr. Chaithra R; 
  • Dr. Shubham Agarwal; 
  • Dr. Chitrakshi Nagpal; 
  • Dr. Gagantej B H; 
  • Dr. Umang Arora; 
  • Dr. Kartikrya Kumar Sharma; 
  • Dr. Ranveer Singh Jadon; 
  • Ashish Datt Upadhyay; 
  • Dr. Neeraj Nischal; 
  • Dr. Naval K Vikram; 
  • Dr. Manish Soneja; 
  • Dr. R M Pandey; 
  • Dr. Naveet Wig

ABSTRACT

Background:

Seroprevalence of IgG antibodies against SARS-CoV-2 is an important tool to estimate the true extent of infection in a population. However, seroprevalence studies have been scarce in South East Asia including India, which, as of now, carries the third largest burden of confirmed cases in the world. The present study aimed to estimate the seroprevalence of anti-SARS-CoV-2 IgG antibody among hospitalized patients at one of the largest government hospital in India

Objective:

The primary objective of this study is to estimate the seroprevalence of SARS-CoV-2 antibody among patients admitted to the Medicine ward and ICU

Methods:

This cross-sectional study, conducted at a tertiary care hospital in North India, recruited consecutive patients who were negative for SARS-CoV-2 by RT-PCR or CB-NAAT. Anti-SARS-CoV-2 IgG antibody levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum sample by the ELISA method

Results:

A total of 212 hospitalized patients were recruited in the study with mean age (±SD) of 41.2 (±15.4) years and 55% male population. Positive serology against SARS CoV-2 was detected in 19.8%patients(95% CI 14.7-25.8). Residency in Delhi conferred a higher frequency of seropositivity 26.5% (95% CI 19.3-34.7) as compared to that of other states 8% (95% CI 3.0-16.4) with p-value 0.001. No particular age groups or socio-economic strata showed a higher proportion of seropositivity

Conclusions:

Around, one-fifth of hospitalized patients, who were not diagnosed with COVID-19 before, demonstrated seropositivity against SARS-CoV-2. While there was no significant difference in the different age groups and socio-economic classes; residence in Delhi was associated with increased risk (relative risk of 3.62, 95% CI 1.59-8.21)


 Citation

Please cite as:

Ray DA, Singh DK, Chattopadhyay S, Mehdi F, Batra DG, Kumari DA, Agarwal DA, M DB, Sahni DS, R DC, Agarwal DS, Nagpal DC, B H DG, Arora DU, Sharma DKK, Jadon DRS, Upadhyay AD, Nischal DN, Vikram DNK, Soneja DM, Pandey DRM, Wig DN

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India

JMIR Preprints. 28/08/2020:23937

DOI: 10.2196/preprints.23937

URL: https://preprints.jmir.org/preprint/23937

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.